These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32195987)

  • 1. Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
    Corona A; Agarossi A; Veronese A; Cattaneo D; D'Avolio A
    Ther Drug Monit; 2020 Apr; 42(2):165-168. PubMed ID: 32195987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
    Roecker AM; Pope SD
    Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
    Van Matre ET; Teitelbaum I; Kiser TH
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin.
    Anderson VR; Keating GM
    Drugs; 2008; 68(5):639-48; discussion 649-51. PubMed ID: 18370443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin for infective endocarditis: a single centre experience.
    Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
    J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.
    Lafon-Desmurs B; Gachet B; Hennart B; Valentin B; Roosen G; Degrendel M; Loiez C; Beltrand E; D'Elia P; Migaud H; Robineau O; Senneville E
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1475-1480. PubMed ID: 38753112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Ramdeen S; Boucher HW
    Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.
    Dash RP; Babu RJ; Srinivas NR
    Infect Dis (Lond); 2017 Jul; 49(7):483-492. PubMed ID: 28264598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.
    Rappo U; Dunne MW; Puttagunta S; Baldassarre JS; Su S; Desai-Krieger D; Inoue M
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31501147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.